2016 Press Releases

 

December 13, 2016 Cognition Therapeutics initiates US clinical testing of CT1812, a novel strong molecule for the potential treatment of Alzheimer’s disease
December 5, 2016 Cognition Therapeutics to Highlight CT1812 Safety Data at the 9th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
November 30, 2016 Society for Neuroscience 2016 Nanosymposium Explores Potential of “Sigma-2/PGRMC1 Receptor Function in Disease and Therapeutics”
November 23, 2016 CogRx Sees Lilly Solanezumab Results as Support for its Unique Mechanism for Treatment of Alzheimer’s Disease
November 16, 2016 CogRx Founder and CSO, Dr. Susan Catalano, will co-chair nanosymposium at the Society for Neuroscience 2016 Annual Meeting
November 11, 2016 Cognition Therapeutics Announces Dosing of First Alzheimer’s Patient in Phase 1b Trial of CT1812
October 28, 2016 Alzheimer’s Drug Development Company Cognition Therapeutics appoints Kenneth I. Moch President & CEO
September 29, 2016 Cognition Therapeutics (CogRx) Receives Michael J. Fox Foundation Grant to Study Inhibitors of Alpha-synuclein Oligomers for the Treatment of Parkinson’s Disease

 

2015 Press Releases

 

September 18, 2015 Cognition Therapeutics Commences Clinical Trials in Melbourne
September 8, 2015 Cognition Therapeutics Completes Oversubscribed $12 Million Series B Financing

 

2014 Press Releases

 

May 21, 2014 NIH to Fund CogRx’s Strong Molecule Soluble Abeta Receptor Antagonist Program for Treatment of AD
May 21, 2014 Cognition Therapeutics’ Selected for Support by National Institute on Aging
April 1, 2014 Cognition Therapeutics, Inc. (CogRx) receives a US Patent for a Drug to Fight Alzheimer’s Disease